Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial gemcitabine versus continued intravenous gemcitabine plus nab-paclitaxel after induction chemoradiotherapy for unresectable locally advanced pancreatic cancer
2019-002288-84Phase 3Completed
- Sponsor
- RenovoRx
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) comparing Targeted intra-arterial gemcitabine with Continued intravenous gemcitabine plus nab-paclitaxel (2 arms). Primary endpoint: Overall survival. Started Jun 2019; status: completed.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2019-002288-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002288-84.